T3	eligibility 808 832	Adult patients with TNBC
T4	total-participants 1071 1081	Forty-five
T5	control-participants 1106 1108	18
T6	intervention-participants 1145 1147	21
T7	control 1118 1140	cyclophosphamide alone
T8	outcome 1209 1220	Lymphopenia
T9	outcome 1360 1379	objective responses
T10	cv-bin-abs 1280 1283	One
T11	iv-bin-abs 1331 1332	2
T12	outcome 1381 1395	Response rates
T13	outcome 1400 1432	median progression free survival
T1	intervention 29 107	cyclophosphamide and the oral poly (ADP-ribose) polymerase inhibitor veliparib
